| abstract |
The present invention provides engineered lymphocytes (e.g., γδ T cells, NK cells, NK-like T cells, engineered innate lymphoid cells, or MAIT cells) comprising a heterologous targeting construct lacking an intracellular signaling domain capable of activating the lymphocyte on which the construct is expressed. Further provided are compositions of engineered lymphocytes (e.g., γδ T cells) and methods of using the engineered lymphocytes (e.g., γδ T cells, e.g., a part of an adoptive T cell therapy). |